|Day Low/High||2.30 / 2.43|
|52 Wk Low/High||0.67 / 2.67|
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
We're initiating a position in drug-delivery system developer Antares Pharma, which we think can double from current levels.
While there are many reasons why insiders may sell a stock, there's really only one reason they purchase on the open market -- to make money.
The Company's First New Drug Application Utilizing QuickShot® Technology
Investors in Antares Pharma Inc. saw new options begin trading this week, for the August 2017 expiration.
Teriparatide Injection Represents the First Product Approved in Europe Utilizing Antares' Multi-Dose Pen Technology
Record Product Sales Drive Third Quarter Results
QuickShot® Testosterone Data Has Been Selected for Both Oral and Poster Presentations
Analysis of 26 Week Safety Data From Study QST-15-005 Completed, NDA Submission Remains on Track for Fourth Quarter 2016
The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.
Significant Growth in Product Sales Drive Second Quarter Results
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc.
Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017
The most recent short interest data was recently released for the 03/31/2016 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 21.61 "days to cover" versus the median component at 6.18.
Last Patient Completes Treatment in QuickShot Supplemental Safety Study QST-15-005
The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 1,852,957 share decrease in total short interest for Antares Pharma Inc. , to 9,381,683, a decrease of 16.49% since 04/15/2016.
Total Revenues of $12.3 million increased 48% Over Q1 2015